[breadcrumb_custom]

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) – Analysts’ Views Change

In the last trading session, 3.28 million Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares changed hands as the company’s beta touched 1.26. With the company’s per share price at $2.39 changed hands at $0.09 or 3.91% during last session, the market valuation stood at $585.38M. LXRX’s last price was a discount, traded about -58.58% off its 52-week high of $3.79. The share price had its 52-week low at $0.92, which suggests the last value was 61.51% up since then. When we look at Lexicon Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 3.94 million shares, with the 3-month average coming to 1.14.

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information

Instantly LXRX was in green as seen at the end of in last trading. With action 12.21%, the performance over the past five days has been green. The jump to weekly highs of 2.44 added 3.91% to the stock’s daily price. The company’s shares are showing year-to-date upside of 56.21%, with the 5-day performance at 12.21% in the green. However, in the 30-day time frame, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is 64.83% up. Looking at the short shares, we see there were 23.03 million shares sold at short interest cover period of 6.35 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts

Data shows that the Lexicon Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 38.95% over the past 6 months, a -30.65% in annual growth rate that is considerably lower than the industry average of 15.50%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 12.05%. The 2024 estimates are for Lexicon Pharmaceuticals Inc earnings to decrease by -26.81%.

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.48% of Lexicon Pharmaceuticals Inc shares while 80.41% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 81.61%. There are 80.41% institutions holding the Lexicon Pharmaceuticals Inc stock share, with Artal Group S.A. the top institutional holder. As of Jun 29, 2023, the company held 48.00% of the shares, roughly 117.55 million LXRX shares worth $269.2 million.

BVF Inc. holds the second largest percentage of outstanding shares, with 8.16% or 20.0 million shares worth $45.79 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund. With 3.7 million shares estimated at $8.48 million under it, the former controlled 1.51% of total outstanding shares. On the other hand, Fidelity Growth Company Fund held about 1.03% of the shares, roughly 2.53 million shares worth around $4.35 million.

On Key

Related Posts